• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Drugs

  • Print
  • Share
  • E-mail

Role of Naloxone in Opioid Overdose Fatality Prevention; Request for Comments; Public Workshop

The Food and Drug Administration (FDA), Center for Drug Evaluation and Research (CDER), in collaboration with the Office of the Assistant Secretary for Health, National Institutes of Drug Abuse and the Centers for Disease Control and Prevention, is announcing a scientific workshop to initiate a public discussion about the potential value of making naloxone more widely available outside of conventional medical settings to reduce the incidence of opioid overdose fatalities. Academia, government, industry experts and patient advocates will be assembled to discuss which populations are at-risk for opioid overdose and how public health groups are working together to curb the abuse of opioids. We will also seek to identify potential health concerns, social concerns, legal concerns, regulatory issues and future research needs related to making naloxone more widely available.

Date:         April 12, 2012

Time:         8:30 a.m. to 5:30 p.m.

Location:   FDA White Oak Campus
                  10903 New Hampshire Avenue
                  Bldg. 31 Conference Center
                  Silver Spring, MD 20993

 

Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance